---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-22-000016"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:56:40.785050+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tarsus Q1 net loss $20.2M; TP-03 hits all endpoints in Saturn-2 Phase 3

## Summary
- Q1 net loss $20.2M vs net income $10.4M YoY; license revenue $0.5M vs $33.4M.
- TP-03 met primary and all secondary endpoints in Saturn-2 Phase 3 for Demodex blepharitis; NDA submission H2 2022.
- Cash $175.3M at March 31; completed $71M net equity raise in May; cash runway into at least 2026.
- TP-05 Phase 1b Callisto data expected H2 2022; TP-04 Phase 2 for rosacea planned.

## SEC filing metadata
- accession: 0001819790-22-000016
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000016/0001819790-22-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000016/tars-20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-22-000016
- JSON: https://secwatch.observer/filing/0001819790-22-000016.json
- Plain text: https://secwatch.observer/filing/0001819790-22-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.